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Abstract The primary structure of two forms of gonadotropin 
releasing hormone (GnRH) from tunicate {Chelyosoma produc-
tuni) have been determined based on mass spectrometric and 
chemical sequence analyses. The peptides, tunicate GnRH-I and 
-II, contain features unprecedented in vertebrate GnRH. 
Tunicate GnRH-I contains a putative salt bridge between Asp0 
and Lys8. A GnRH analog containing a lactam bridge between 
Asp5 and Lys8 was found to increase release of estradiol 
compared with that of the native tunicate GnRH-I and -II. 
Tunicate GnRH-I I contains a cysteine residue and was isolated 
as a dimeric peptide. These motifs suggest that the conformation 
plays an important role in receptor activation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The neuropeptide gonadotropin releasing hormone (GnRH) 
is secreted in the median eminence of vertebrates to act on the 
anterior pituitary gland resulting in the release of luteinizing 
hormone and follicle stimulating hormone. The release of 
these hormones sets off a cascade of events leading to steroi-
dogenesis. Because of the pivotal role of GnRH in vertebrate 
reproduction, the primary structures of GnRH peptides in a 
wide variety of species have been determined. In most verte-
brates more than one form of GnRH is encountered, e.g. 
chicken GnRH-I and -II are both decapeptides with consid-
erable identity to GnRH peptides from other species (see Ta-
ble 1). In fact, the primary structures of these different forms 
of GnRH show considerable conservation particularly at res-
idues \-A and 9-10 (e.g. chicken GnRH-I and -II differ only 
at residues 5, 7 and 8). Also, in mammals, two forms of the 
GnRH decapeptide have been found. This raises the question 
from which forms of GnRH, conserved throughout evolution, 
did these peptides arise? 
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Evolutionary studies have attempted to interpret the varia-
tion in primary structure of GnRH peptides in terms of the 
hormone structure and its function. These phylogenetic argu-
ments have in turn stimulated systematic synthetic investiga-
tions aimed at identifying antagonists or super agonists [1,2]. 
These agonists and antagonists have potential pharmacologi-
cal value in management of sex steroid-dependent pathophysi-
ologies. 
Previously we and others have traced the structural changes 
in the evolution of this neuropeptide within vertebrates from 
the single form of mammalian GnRH through to primitive 
species such as Russian sturgeon {Acipenser gueldenstaedti) 
[3], spiny dogfish (Squalus acanthias) [4], and lamprey (Petro-
myzon marinus) [5]. In phylogenetic terms, these species are 
located in three different lineage bifurcations, the first leading 
to bony fishes, the second leading to cartilaginous fishes, and 
the third to jawless fishes. We are interested in continuing to 
trace the phylogeny of this neuropeptide and to establish 
whether a homolog exists in invertebrates. To address this 
issue we have investigated whether a GnRH-like molecule 
was present in tunicate {Chelyosoma productum). Protochor-
dates such as the tunicate or sea squirt are at an evolutionary 
junction because they possess a notochord during the larval 
stage of development, which they loose when they become 
sedentary. 
The introduction of electrospray [6] and matrix assisted 
laser desorption (MALD) [7-9] ionization techniques to 
mass spectrometry (MS) has resulted in a dramatic increase 
in sensitivity, allowing the analysis of fmol amounts of small 
peptides [9,10]. Although MALD has been successfully 
coupled with a number of types of mass spectrometers includ-
ing magnetic deflection [6,11], Fourier transform ion cyclotron 
resonance [12] and quadrupole ion trap [13] instruments, it 
remains most commonly used with time of flight (TOF) 
mass analyzers [9]. A major advantage of TOF is the essen-
tially unlimited mass range as demonstrated by the observa-
tion of ions in excess of 1 MDa [14]. In MALD, the high 
energy transfer used to effect ionization results in a small 
variation in the initial kinetic energy and position of the 
ions that are formed. As a result the mass accuracy of 
MALD-TOF is significantly reduced compared to that typi-
cally associated with conventional MS techniques. In order to 
correct for these effects with a TOF instrument, a reflector or 
energy analyzer can be incorporated into the design of the 
instrument. A more efficient TOF method of increasing the 
mass accuracy is the introduction of a time delay after ion 
formation but before the ions are accelerated out of the ion-
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ization source [15]. Alternatively, the analysis can be carried 
out with an instrument that can compensate and select for the 
spread in energies of the ions such as a double focusing mag-
netic sector type instrument. 
The initial attempts to improve the mass accuracy by incor-
porating a reflector, ultimately led to an extremely useful 
method of fragment mass analysis [16]. The reflector can be 
used for analyzing the energy of fragment ions. Fragment ions 
formed from parents that have exited from the ionization 
source (and thereby experienced full acceleration) are referred 
to as post source decay (PSD) ions and have energies propor-
tional to their mass. By reducing the energy applied to the 
reflector it is possible to bring these PSD ions to focus on the 
detector. The generation of PSD sequence information has 
been demonstrated for intact ions formed with MALD [17]. 
PSD with MALD has been used to investigate the structure of 
peptides [18-21], glycopeptides [22], phosphopeptides [23] and 
oligosaccharides [24]. 
GnRH peptides have historically been difficult to sequence 
because of the presence of blocked N- and C-termini (pGlu 
and amide). Whereas the N-terminal pyroglutaminyl residue 
can be cleaved by the enzyme pyroglutamate aminopeptidase 
[25], the C-terminal amide functionality is resistant to carboxy 
peptidase treatment [26]. In our hands pyroglutamate amino-
peptidase has worked reliably at the cost of additional mate-
rial and the additional purification step [27]. Therefore, 
GnRH is representative of that class of samples where the 
sensitivity of an MS based sequencing strategy has additional 
complementary advantages over the Edman based chemical 
approach. 
Part of this work has been reported previously at the 44th 
American Society for Mass Spectrometry and Allied Topics in 
Portland, May 1996. 
2. Materials and methods 
The tissue collection, peptide extraction and purification of native 
tunicate GnRH peptides from Chelyosoma productum have been de-
tailed previously [28]. 
2.1. Mass spectrometry 
All MALD measurements were made using a nitrogen UV laser 
(Laserscience) and a-cyano-4-hydroxycinnamic acid, (Aldrich) which 
was dissolved (without further purification) in acetone (Sigma). An 
aliquot (0.5 uL) of the matrix solution was applied to stainless steel 
targets [29]. Samples were subsequently applied to the thin matrix film 
and left to dry. Repetitive applications (2-20 times) of the sample on 
or about the same spot were used to increase the amount of sample 
applied. Care was taken to avoid spreading of solutions and thereby 
lowering the concentrations of the sample. However, no special pre-
cautions were made to reduce or contain the sample area since the 
TOF instrument does not incorporate any means for visually locating 
the sample and directing the laser onto a small sample area. Reduc-
tion of disulfide bridges was carried out with tris(2-carboxyethyl) 
phosphine prepared as described elsewhere [30]. 
2.1.1. TOF measurements. Intact and PSD MALD measurements 
were carried out on a Reflex (Bruker Instruments Inc. Billerica, MA) 
reflectron TOF mass spectrometer equipped with a 100 MHz digitizer. 
The instrument was operated with direct extraction and without pre-
cursor selection. The accelerating voltage was +31 kV and a varying 
potential (0-30 kV) was applied to the reflector. The mass accuracy in 
the reflector mode with external calibration of the instrument was 
typically better than 1000 p.p.m. The spectra represent the accumu-
lation of data from approximately 20-50 laser shots. 
2.1.2. Magnetic sector measurements. Accurate mass measure-
ments were carried out on a JMS HX110 (Jeol, Japan) double focus-
ing magnetic sector instrument equipped with a JUS MALD ioniza-
tion source (Jeol USA, Peabody, MA). The instrument was operated 
at 10 kV accelerating voltage and with —20 kV post acceleration on to 
a point detector (Jeol, Japan). Based on the observed TOF mlz, a 
narrow mass range scan (< 50 Da) was generated at constant magnet 
field strength by rapidly (< 0.2 s) varying the accelerating voltage and 
electric field strength. The detector signal was dampened by selecting a 
300 Hz filter and the sampling rate was increased by setting the de-
sired resolution acquisition parameter to 10000. The instrument slit 
width settings were set to give a nominal resolution of 3000. The 
spectra represent the accumulation of 15000-18000 scans where the 
laser was operated independently of the scan rate at 5 Hz. These 
measurements resulted in resolved isotope distributions albeit with a 
low level of statistical significance. In order to increase the statistical 
significance we used the sum of the observed masses for major iso-
topomers in each distribution. Because the separation between the 
isotopomers is not exactly 1 Da, we subtracted the mass correspond-
ing with the difference between the mass of the 12CX and
 12C^LiC or 
^C^ljC and 12Cj.L2C2 etc., isotopomers of similar mass GnRH mol-
ecules. This results in an observed mean monoisotopic mass which can 
be compared with the calculated monoisotopic mass for the sequence 
proposed. Both internal calibration (Fig. 6) where the calibrant was 
mixed with the sample on the probe or external calibration (Fig. 11) 
where the probe was withdrawn and replaced with a sample contain-
ing the calibrant were used to calibrate the mass scans. The mass 
accuracy of this instrument when operated as described with external 
calibration is better than 20 p.p.m. 
2.2. Sequence analysis 
Chemical sequence analysis was carried out using an Applied Bio-
systems 470A Protein Sequencer equipped with an on-line PTH de-
tector. Pyroglutamate aminopeptidase treatment was performed as 
described elsewhere [27]. 
2.3. Synthesis 
The synthesis and purification of the synthetic GnRH peptides has 
previously been described [28]. 
2.4. GnRH injection and steroid assay 
Peptides were separately injected (1 ul of 10-3 M) into the heart 
(visceral hemocoel) near the gonads in 15 tunicates/group at a stage of 
reproduction in which sperm was present in the sperm duct, but eggs 
were not yet in the oviduct. Samples were pooled from each group 
and extracted for steroids. After treatment the gonads were removed, 
frozen, pooled, powdered and extracted in ammonium sulfate (15 mL, 
pH 1) with diethyl ether/ethanol (60 mL, 4:1, v:v). The ether/ethanol 
phase was evaporated under nitrogen. The fluoroimmunoassay (Au-
todelfia) of the extract used europium-labeled steroids and specific 
antisera for estradiol 17pS, progesterone and testosterone. Serial dilu-
tions were necessary for two estradiol samples and for all progester-
one samples. In Fig. 11, the gonad was dissected at time 0 for the 
control (Cont.) animals that were not injected (no inj.) or at 6 or 24 h 
from injected individuals from each group. 
3. Results and discussion 
Tunicates were dissected and the dorsal portion of the ani-
mal including the cerebral ganglion, the neural gland and the 
dorsal strand (see Fig. 1) was removed and collected. Two 
compounds (tunl and tunH) cross-reacting with antisera raised 
against lamprey GnRH were isolated from extracts of this 
material. The spectrum shown in Fig. 2, was obtained from 
the HPLC purified first immunoreactive fraction (tunl) using 
MALD-TOF-MS. In this spectrum (Fig. 2) a single species 
was observed at mlz 1245.8. This mass was not consistent 
with any of the known forms of vertebrate GnRH's (see 
Table 1). Based on the purification protocol and this mass 
measurement we could deduce that tunl was not a known 
GnRH. 
The post-source decay (PSD) spectrum of the intact proton-
ated molecule ion observed from tunl is shown in Fig. 3. A 
number of intense fragment ions observed were indicative of 
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Fig. 1. Schematic drawing of the adult tunicate Chelyosoma productum indicating the location of the dorsal strand plexus containing GnRH 
cells and its proximity to the gonaducts and the gonad. To illustrate the inside of the tunicate, the drawing bisects the animal with a flap of tis-
sue drawn to the right. 
GnRH peptides as explained below. Fig. 4A shows the low-
mass region of PSD spectrum of 1 pmol of mammalian 
GnRH where several intense fragment ions are indicated 
y2+2, a2, b2, b3, a4, b4 [31,32]. The PSD spectrum of 10 
pmol of mammalian GnRH contained similar fragment ions 
as observed in Fig. 4A (with a higher signal to noise ratio) 
while no distinct fragment ions were observed from 0.1 pmol 
of mammalian GnRH (data not shown). Based on the inten-
sity of the MALD spectra and the UV absorbance we esti-
mate that 1-2 pmol of peptide was applied to the probe for 
the tunl PSD analysis shown in Fig. 3. The fragment ions 
indicated in Fig. 4A arise as a result of peptide chain cleavage 
with charge retention in the conserved region of GnRH (i.e. 
residues \-4 and 9-10). The low-mass region of the tunl PSD 
spectrum is shown in Fig. 4B. The appearance of the spectra 
shown in Fig. 4A and B are very similar. In particular, the 
low mass fragment ions labeled in Fig. 4B are observed at the 
same mlz in the PSD spectra of most other GnRH peptides 
(see Table 2). Although the cross reactivity with antisera and 
the intact mass suggested that tunl was a novel GnRH, the 
similarity between the spectra in Fig. 4 (and the data in Table 
2) was the first direct evidence that the peptide was a novel 
GnRH. 
The similar mlz and intensity of many of the low mass 
fragment ions observed for tunl in Fig. 4B and other GnRH 
peptides in Table 2, were taken to indicate that tunl also 
contained the same conserved regions as mammalian 
GnRH. The mlz 172.2, 221.7, 250.2, 435.0, 494.2 and 521.8 
fragment ions were therefore assigned as y2+2, a2, b2, b3, a4, 
b4. These assignments were used as a template for interpreta-
tion of the remainder of the spectrum. Those fragment ions 
observed in the high-mass region of the tunl PSD spectrum 
(Fig. 5) whose mlz did not coincide with the fragment ions 
observed in mammalian GnRH were assumed to arise as a 
result of peptide chain cleavage with charge retention on a 
portion of the molecule not corresponding to the conserved 
region of GnRH. In addition, we assumed that as was the 
case with most GnRH peptides, the high mass fragment 
ions were of N-terminal origin (compare Tables 1 and 2). 
Further, in Fig. 5 fragment ions observed at mlz 772.2, 
800.1 and mlz 919.1, 947.2 appeared to correspond with 'a' 
and 'b' type N-terminal fragment ions (since the mass differ-
Table 1 
C-terminal fragment ions observed from different GnRH peptides 
Species Sequence Massa y2+2 y3+2 y4+2 *z5
by5+2 y6+2 y7+2 y8+2 
mammalian 
dogfish III 
salmon 
chicken II 
catfish 
chicken I 
herring II 
sea bream 
lamprey III 
tunicate I 
tunicate II 
ZHWSYGLRPG 
ZHWSHGWLPG 
ZHWSYGWLPG 
ZHWSHGWYPG 
ZHWSHGLNPG 
ZHWSYGLQPG 
ZHWSHGLSPG 
ZHWSYGLSPG 
ZHWSHDWKPG 
ZHWSDYFKPG 
ZHWSLCHAPG 
1182.58 
1186.55 
1212.56 
1236.53 
1114.52 
1154.54 
1087.51 
1113.51 
1259.57 
1246.56 
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Fig. 2. MALD-TOF mass spectrum of tunGnRH-I. 
ence between these fragment ions was 27.9 and 28.2 Da). We 
therefore assumed that m/z 800.1 and 947.3 were 'b' type 
fragment ions. The mass difference between m/z 521.8 and 
800.1 (278.3 Da) corresponds with the sum of either tyrosine 
and aspartic acid (278.26 Da) or methionine and phenylala-
nine (278.38 Da). Inspection of the spectrum allows us to 
exclude the Met-Phe possibility and determine the order of 
the Tyr-Asp interpretation. Based on the intensity of, and 
mass difference between, the m/z 521.8 and 637.2 fragment 
ions (115.4 Da) we assigned the m/z 637.2 fragment ion as 
bs and the fifth residue as Asp. The mass difference between 
m/z 637.2 and m/z 800.1 fragment ions (162.9 Da) confirms 
our suggestion that the m/z 800.1 was derived by 'b ' type 
cleavage and indicates the sixth residue is Tyr. The difference 
between m/z 800.1 and 947.2 (147.1 Da) is in accordance with 
our suggestion that the m/z 947.3 fragment ion was a 'b' type 
ion and indicates that the seventh residue was phenylala-
nine. The mass difference between the m/z 947.3 and 1074.1 
(126.9 Da) corresponds most closely with either glutamine 
(128.06 Da) or lysine (128.10 Da). We assigned the eighth 
residue as lysine on the basis of the intense m/z 300.1 fragment 
ion assigned as y3+2 and also observed for mammalian 
GnRH which contains a basic amino acid (arginine) in posi-
tion 8. Finally, the mass difference between m/z 1074.1 and the 
intact [M+H]+ m/z 1245.8 (171.7 Da) corresponds with Pro-
Gly (170.19 Da). 
We note that the PSD fragmentation could not be used to 
distinguish between the order of the first two amino acids (i.e. 
pGlu-His versus His-pGlu). Although, His-pGlu is non-sensi-
cal, the absence of significant fragmentation between these 
two residues permits alternative assignments (e.g. Thr-Phe 
(248.28 Da) cannot be distinguished from pGlu-His (248.24 
Da)). Similarly, the PSD fragmentation cannot distinguish 
between the order Pro-Gly or Gly-Pro at the C-terminus of 
the peptide. In each case the sequence was deduced based on 
the presumed identity with all other known GnRH peptides. 
In addition, an aliquot (corresponding to 10 X the amount of 
sample applied for MALD PSD analysis) of the sample was 
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Fig. 3. PSD spectrum of tunGnRH-I. 
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Fig. 4. Low-mass region (100-600 Da) of PSD spectrum of (A) mammalian GnRH and (B) tunGnRH-I. 
treated with pyroglutamate aminopeptidase. In this way we 
were able to exclude either Thr-Phe or Phe-Thr on the basis of 
the shift in retention time and observed mass after pyrogluta-
mate aminopeptidase treatment (data not shown). Chemical 
sequence analysis after HPLC purification yielded the se-
quence assignment (H)(W)SDYF(K)PG, where residues in pa-
Table 2 
N—terminal fragment ions observed from different GnRH peptides 
Species Sequence a2 b2 b3 a4 *4
a b4 a5 *5b b5 a6 b6 a7 b7 a8 b8 
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Fig. 5. High-mass region (500-1100 Da) of PSD spectrum of tunGnRH-I. 
rentheses were assigned with less than 50% confidence. This 
analysis also resolved the assignment of the C-terminal resi-
dues. Therefore based on the PSD measurement and chemical 
sequence analysis we proposed the sequence pGlu-His-Trp-
Ser-Asp-Tyr-Phe-Lys-Pro-Gly. 
In order to verify the proposed sequence and also to iden-
tify whether the carboxy-terminus of the molecule was am-
idated a more accurate mass measurement was undertaken. 
Using M A L D with the magnetic sector instrument (as de-
scribed in the experimental section) the free acid and amidated 
forms of bombesin and a G n R H analog were analyzed (data 
not shown). Although the intensity of different isotopomers 
were observed to vary in consecutively measured spectra, the 
monoisotopic isotopomer could be clearly identified in each 
spectrum and thereby the difference between the two forms of 
the peptides determined. In addition, to the [ M + H ] + species 
we observed intense isotopomer distributions for the 
[ M + N a ] + and [ M + K ] + species which could be used to confirm 
the monoisotopic peak in each distribution and thereby the 
100 
o 50-
molecule mass (M). Fig. 6 shows the resolved isotope distri-
butions of the [M+H]+ and [ M + N a ] + species from tunl (an 
internal calibrant chicken G n R H - I I (denoted as C) present on 
the probe generated [C+Na] + and [C+K] + species). The ob-
served mlz of 1246.58 compares very closely with that calcu-
lated for the monoisotopic [M+H]+ of 1246.564 D a for the 
amidated form of the proposed sequence. Based on these 
analyses we assign tunl as a G n R H , t u n G n R H - I (sequence 
as listed in Table 3). 
Purification of the second immunoreactive fraction (tunll) 
led to the identification of a major component which when 
analyzed with M A L D - T O F - M S gave a single species at mlz 
2233A (Fig. 7A). This mass was significantly greater than that 
of the 11 known forms of vertebrate G n R H . This component 
appeared to be a n o n - G n R H that shared some common 
G n R H epitope and therefore cross-reacted with the antisera 
used (based on the orthogonal purification protocol, we could 
discount the possibility that an impurity of this mass was 
present that was more abundant than a minor G n R H compo-
[C+Na]+ 
[C+K]+ 
itykt^UMMMw 
[M+H]+ 
1230 1255 
"T T" ^ r 
1280 
m/z 
Fig. 6. Accurate mass measurement of the [M+H]+ of tunGnRH-I. 
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Fig. 7. MALD-TOF mass spectra of tunGnRH-II (a) before and (b) after reduction. 
nent). However, the PSD spectrum of the protonated mole-
cule ion (shown in Fig. 8) contained fragment ions at mlz 
110.7, 172.3, 209.7, 248.7, 436.1, 505.8, 522.8 and 583.4. The 
observed masses of several of these fragment ions (mlz 110.7, 
172.3, 248.7, 436.1, 505.8 and 522.8) are consistent with those 
observed in the low-mass region of known GnRH peptides 
(see Fig. 4 and Table 2). This suggested that tunll also con-
tained regions with sequence identity to GnRH peptides. The 
situation was further clarified after treatment of the fraction 
with pyroglutamate aminopeptidase. Re-purification and 
measurement with MALD-TOF-MS revealed a species at mlz 
1006.0 (data not shown). Because the enzyme treatment was 
carried out in a buffer containing the reducing agent DTT, we 
investigated the effect of reduction alone on the second im-
munoreactive fraction. After addition of the reducing reagent 
(TCEP) [33] we observed a shift in the retention time of the 
tunll fraction. MALD-TOF-MS analysis of this fraction gave 
a species at mlz 1118.4 (see Fig. 7B), indicating that the pep-
tide present in this fraction was a cystine-containing homo-
dimer and explaining the species observed at mlz 1006.0 after 
pyroglutamate aminopeptidase treatment. Both the intact 
mass (see Fig. 7B and Table 1) and the presence of a cysteine 
residue indicated that the peptide monomer was not a known 
GnRH. The low-mass region of the PSD spectrum of the 
protonated molecule ion of the reduced monomer is shown 
in Fig. 9. An uncharacteristic pattern was observed as a result 
of superimposition of the typical GnRH fragments with other 
intense fragment ions. Extending from the familiar mlz 172.3 
1.0 
c 
0.5 
J3 
GO 
< 
0 
172.3 522.8 
583.4 
2233.1 
O 
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Fig. 8. Low-mass region (50-600 Da) of PSD spectrum of dimeric tunGnRH-II. 
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Fig. 9. Low-mass region (100-600 Da) of PSD spectrum of monomeric tunGnRH-II. 
(y2+2) to the mlz 243.1 fragment ions we observe a mass 
separation of 71 Da consistent with alanine. The separation 
between the mlz 243.1 and 380.1 (137 Da) corresponds with 
histidine, while the separation to mlz 483.3 (103.2 Da) indi-
cates cysteine. The presence of cysteine is confirmed by experi-
ments detailed above. This information suggests the sequence 
Cys-His-Ala-Pro-Gly for the C-terminus. The high-mass re-
gion of the tunll PSD spectrum is shown in Fig. 10. The 
mass separation between the mlz 522.2 (b4) and the intense 
mlz 738.4 (216.2 Da) can correspond with either threonine-
aspartic acid, serine-glutamic acid or leucine-cysteine. The 
presence of a fragment at mlz 635.6 favors the leucine-cysteine 
sequence assignment. The separation between the mlz 875.9, 
738.4 and 945.6 verified the presence of the His-Ala residues. 
Chemical sequence analysis carried out on an aliquot after 
pyroglutamate aminopeptidase treatment led to the sequence 
assignment X(W)SL(C)HAPG, where X designates that no 
residue could be assigned confidently and residues in paren-
theses were assigned with less than 50% certainty. On the basis 
of this PSD measurement and chemical sequence analysis we 
proposed the sequence pGlu-His-Trp-Ser-Leu-Cys-His-Ala-
Pro-Gly for the monomeric form. Accurate mass measure-
ment were obtained using external calibration with MALD 
on the magnetic sector instrument. Fig. 11A shows the re-
solved isotope distribution of the [M+H]+, [M+Na]+ and 
[M+K]+ species generated from tunll, before reduction where 
the monoisotopic [Md+H]+ species was observed at mlz 
2232.08 (cf. 2231.977 for the calculated monoisotopic 
[Ma+H]+ where Ma denotes the cystine-containing dimer). 
Fig. 1 IB shows the resolved isotope distribution of the 
-216.2 137.5- —69.7-*—172.8 
Q1H8.4 
875.9 ° ° ° 
945.6 
907.3 
977.6 
Fig. 10. High-mass region (500-1000 Da) of PSD spectrum of monomeric tunGnRH-II. 
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Fig. 11. Accurate mass measurement of the [M+H]+ of tunGnRH-II (A) before reduction and (B) after reduction. 
[M+H]+, [M+Na]+ and [M+K]+ after reduction (with TCEP) 
where the monoisotopic [Mm+H]+ species was observed at ml 
z 1117.52 (cf. 1117.500 for the calculated monoisotopic 
[ M m + H ]
+ , where M m denotes the cysteine-containing mono-
mer). On the basis of these analyses we assign tunll as 
t unGnRH-I I (sequence as listed in Table 3). 
Based on PSD sequencing information and the identity ob-
served within this class of peptides we have determined the 
amino acid sequence using 1-2 pmol of purified peptide. We 
note that at the sensitivity level that this investigation was 
undertaken the ability to obtain sequence information with 
Edman techniques was essentially unaltered by treating only 
80% of the material with the enzyme pyroglutamate amino-
peptidase (compared with consuming 100%> of the sample). Of 
the remaining material (20%) the use of ca. half to obtain 
PSD and half to obtain accurate mass information gave im-
portant additional information. The low-mass region of the 
PSD spectra proved to be a useful diagnostic tool for identi-
fying G n R H peptides. We note that there was considerable 
synergism between the sequence information obtained from 
the Edman approach and the PSD technique. Finally, we 
found that the localization of basic residues and the conser-
vation of the amino terminus in vertebrate G n R H molecules 
does give rise to a common motif in the P S D spectrum which 
can be used diagnostically when scanning for putative G n R H -
like molecules. 
The sequence of these novel forms of invertebrate G n R H 
have significant substitutions compared with that of previ-
ously known vertebrate G n R H s . Tunicate G n R H - I differs 
from all vertebrate G n R H s at positions 5, 6 and 7. The pres-
ence of Lys in position 8 of t unGnRH- I , has previously been 
observed in lamprey G n R H - I and lamprey GnRH-I I I , but not 
in G n R H ' s from higher vertebrate species. The t unGnRH-I I 
differs from all vertebrate G n R H s at positions 6, 7 and 8. The 
presence of Leu in position 5 of t unGnRH-I I , has previously 
been observed only in lamprey G n R H - I . 
The t u n G n R H - I contains a putative salt bridge between 
residues Asp 5 and Lys8. In mammalian G n R H a number of 
Table 3 
tunl 
tunll 
tunGnRH-I 
tunGnRH-II 
pGlu-His-Trp-Ser-Asp-Tyr-Phe-Lys-Pro-Gly-NH2 
pGlu-His-Trp-Ser-Leu-Cys-His-Ala-Pro-Gly-NH2 
I 
pGlu-His-Trp-Ser-Leu-Cys-His-Ala-Pro-Gly-NH2 
224 A.G. Craig et al.lFEBS Letters 413 (1997) 215-225 
30 -, 
■a 
(0 
c 
o 
-5? 
D) 
a 
I | 0 hours 
0 6 hours after injection 
| 24 hours after injection 
Contr. 
no in]. 
Contr. 
dil. inj. tunGnRH-l tunGnRH-ll cyclo tun-I mGnRHa 
Fig. 12. Content of estradiol (pg/gonad) after injection of GnRH peptides into the tunicate, Chelyosoma productum. Control (Contr.); injection 
(inj.); diluent (dil.); tunicate (tun); gonadotropin-releasing hormone (GnRH); cyclo(5-8)tunicate GnRH-I (cyclo tun-I); [D-Ala6, Pro9-NEt] 
mammalian GnRH agonist (mGnRHa). 
investigations support a proposed beta turn in this general 
location. The presence of a type II beta turn between these 
residues in tunGnRH-I would facilitate the formation of a salt 
bridge between Asp5 and Lys8 (or conversely the attraction 
between the charged groups of these two residues which con-
stitute a salt bridge may result in the beta turn formation) and 
thereby serve to stabilize a bioactive conformation. The val-
idity of these proposals has been investigated by synthesizing 
the lactam bridge stabilized analog of tunGnRH-I [cyclo(5-
8)tunGnRH-I]. Although sex steroids have not been reported 
for Tunicata, we used highly specific antisera to detect estra-
diol, progesterone and testosterone. Both synthetic tunGnRH-
I and -II resulted in a doubling of the gonadal content of 
estradiol after 24 h. The most effective peptide was the lactam 
bridge stabilized cyclo(5-8)tunGnRH-I which was found to 
double and triple estradiol content after 6 and 24 h as com-
pared to the control group injected with diluent. As shown in 
Fig. 12 this analog resulted in higher estradiol release from 
whole tunicates than a potent linear mammalian GnRH ago-
nist, [D-Ala6, Pro9-NEt] mammalian GnRH. This result also 
extends the observation from amphioxus to tunicates that a 
mammalian GnRH analog can induce an increase in estradiol 
[34]. The same gonadal extracts contained progesterone, but 
the treatment had little effect compared with the control 
groups; the average values in all groups ranged from 120 to 
210 pg/gonad (Fig. 12). Testosterone was either below (<0 .3 
nmol/L) or close (0.5-2.1 nmol/L) to the lower level of detec-
tion. Synthetic tunGnRH-I was also tested on 5 Corella by 
placing them in sea water that had a concentration of GnRH 
of 10 - 7 M. Gamete release was not observed although the 
sperm ducts were full of sperm. The synthetic tunGnRH-I 
and -II were also separately injected into the visceral hemo-
coel in the vicinity of the gonads in 13 Corella. A dose of 1 ill 
of 10~3 M peptide did not release the sperm observed to be in 
the sperm duct. Some of the injections with the picospritzer 
contained coloring and showed that the correct space was 
injected and that the color circulated through the heart fol-
lowed by dispersal in the circulatory system. The animals 
continued to live for 3^1 weeks. 
Tunicate GnRH-II is the first 'GnRH-like' peptide to have 
a cystine residue in its sequence. Clearly, tunGnRH-II is more 
than a 'GnRH-like' peptide since each monomer is a deca-
peptide where residues 1-4 and 9-10 are conserved compared 
with all other known forms of GnRH peptides. The dimeric 
structure has no precedent in this peptide hormone family and 
we speculate that this ligand may represent a means to effect 
receptor dimerization. Dimerization of occupied GnRH recep-
tors is sufficient without further aggregation to activate the 
release of luteinizing hormone from porcine pituitary cells 
[35]. Structure function studies of GnRH emphasize the role 
both the N- and C-terminus of the molecule plays in receptor 
binding. The presence of cysteine in position 5 of the mono-
mer would presumably allow the N- and C-terminus of the 
molecule to bind the receptor whereas the cysteine remains 
free to form the disuffide bridge (cystine). The tunGnRH-II 
may illustrate an ancestral mechanism to ensure receptor di-
merization. 
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